Immunomodulation and chronic inflammation are important mechanisms utilized by cancer cells to evade the immune defense and promote tumor progression. Therefore, various efforts were focused on the development of approaches to reprogram the immune response to increase the immune detection of cancer cells and enhance patient response to various types of therapy. A number of regulatory proteins were investigated and proposed as potential targets for immunomodulatory therapeutic approaches including p53 and Snail. In this study, we investigated the immunomodulatory effect of disrupting Snail-p53 binding induced by the oncogenic KRAS to suppress p53 signaling. We analyzed the transcriptomic profile mediated by Snail-p53 binding inhibitor GN25 i...
As a key transcription factor, the evolutionarily conserved tumor suppressor p53 (encoded by TP53) p...
Accumulating evidence indicates that epithelial-to-mesenchymal transition (EMT) might be a key event...
Despite some significant therapeutic breakthroughs leading to immunotherapy, a high percentage of pa...
Understanding the immune compartment of tumors facilitates the development of revolutionary new ther...
p53 is a transcription factor that regulates the expression of genes involved in tumor suppression. ...
Background: During tumorigenesis, cells proliferate unchecked, altering tissue homeostasis and leadi...
The commonly held view of the tumor suppressor p53 as a regulator of cell proliferation, apoptosis a...
Loss of p53 function contributes to the development of many cancers. While cell-autonomous consequen...
The epithelial-to-mesenchymal transition (EMT) is a developmental program frequently reactivated in ...
The tumor suppressor p53 is the most frequently mutated gene in human cancers. Most of the mutations...
Although immunotherapy continues to demonstrate efficacy in a variety of refractory cancers, current...
Differentially from other kinds of Ras, oncogenic K-Ras, which is mutated approximately 30% of human...
International audienceThe epithelial-mesenchymal transition-inducing transcription factor Snail cont...
From MDPI via Jisc Publications RouterHistory: accepted 2021-12-02, pub-electronic 2021-12-07Publica...
The immune system plays a dynamic role in cancer progression. The theory of immunoediting suggests t...
As a key transcription factor, the evolutionarily conserved tumor suppressor p53 (encoded by TP53) p...
Accumulating evidence indicates that epithelial-to-mesenchymal transition (EMT) might be a key event...
Despite some significant therapeutic breakthroughs leading to immunotherapy, a high percentage of pa...
Understanding the immune compartment of tumors facilitates the development of revolutionary new ther...
p53 is a transcription factor that regulates the expression of genes involved in tumor suppression. ...
Background: During tumorigenesis, cells proliferate unchecked, altering tissue homeostasis and leadi...
The commonly held view of the tumor suppressor p53 as a regulator of cell proliferation, apoptosis a...
Loss of p53 function contributes to the development of many cancers. While cell-autonomous consequen...
The epithelial-to-mesenchymal transition (EMT) is a developmental program frequently reactivated in ...
The tumor suppressor p53 is the most frequently mutated gene in human cancers. Most of the mutations...
Although immunotherapy continues to demonstrate efficacy in a variety of refractory cancers, current...
Differentially from other kinds of Ras, oncogenic K-Ras, which is mutated approximately 30% of human...
International audienceThe epithelial-mesenchymal transition-inducing transcription factor Snail cont...
From MDPI via Jisc Publications RouterHistory: accepted 2021-12-02, pub-electronic 2021-12-07Publica...
The immune system plays a dynamic role in cancer progression. The theory of immunoediting suggests t...
As a key transcription factor, the evolutionarily conserved tumor suppressor p53 (encoded by TP53) p...
Accumulating evidence indicates that epithelial-to-mesenchymal transition (EMT) might be a key event...
Despite some significant therapeutic breakthroughs leading to immunotherapy, a high percentage of pa...